
The FDA has adopted a reconciled figure of 408 as the number of drugs jointly approved with Health Canada, amidst a backdrop of growing scrutiny over the safety of injectable peptides. This decision aims to reduce data-integrity risks linked to previously inflated approval counts, as compounding pharmacies gear up for potentially reintroduced peptide therapies amid rising consumer enthusiasm. However, safety fears persist regarding unregulated products, with experts warning of serious health incidents related to improper dosing and lack of quality oversight.
“The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, The New York Times reports.”